Imperial College London
Professor Dragana Milojkovic

ProfessorDraganaMilojkovic

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Practice (Chronic Myeloid Malignancies)
 
 
 
//

Contact

 

+44 (0)20 3313 1627d.milojkovic

 
 
//

Location

 

Cancer CentreHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Maynard:2021:10.1016/j.ijid.2021.02.056,
author = {Maynard, S and Ros-Soto, J and Chaidos, A and Innes, A and Paleja, K and Mirvis, E and Buti, N and Sharp, H and Palanicawandar, R and Milojkovic, D},
doi = {10.1016/j.ijid.2021.02.056},
journal = {International Journal of Infectious Diseases},
pages = {274--276},
title = {The role of ibrutinib in COVID-19 hyperinflammation: a case report},
url = {http://dx.doi.org/10.1016/j.ijid.2021.02.056},
volume = {105},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Continuing ibrutinib in patients with COVID-19 may be advantageous given its immunomodulatory properties and withdrawal of ibrutinib therapy may be detrimental. Further evidence is required to explore the potential therapeutic impact of BTKis and other immunomodulatory agents on the clinical course of COVID-19 as is currently being carried out in a number of clinical trials.
AU  - Maynard,S
AU  - Ros-Soto,J
AU  - Chaidos,A
AU  - Innes,A
AU  - Paleja,K
AU  - Mirvis,E
AU  - Buti,N
AU  - Sharp,H
AU  - Palanicawandar,R
AU  - Milojkovic,D
DO  - 10.1016/j.ijid.2021.02.056
EP  - 276
PY  - 2021///
SN  - 1201-9712
SP  - 274
TI  - The role of ibrutinib in COVID-19 hyperinflammation: a case report
T2  - International Journal of Infectious Diseases
UR  - http://dx.doi.org/10.1016/j.ijid.2021.02.056
UR  - https://www.sciencedirect.com/science/article/pii/S1201971221001429?via%3Dihub
UR  - http://hdl.handle.net/10044/1/86110
VL  - 105
ER  -
Download